• In Vitro Susceptibility of Staphylococci to Novobiocin and M

  2026-05-25

  This study systematically evaluated the in vitro susceptibility of methicillin-susceptible and methicillin-resistant staphylococci isolated from healthy dogs and those with superficial pyoderma to novobiocin and mupirocin. The findings highlight novobiocin’s variable efficacy against resistant strains, emphasizing the need for informed antimicrobial selection in veterinary research and clinical settings.

• Cy5 TSA Fluorescence System Kit: Signal Amplification in IHC

  2026-05-25

  The Cy5 TSA Fluorescence System Kit unlocks ultra-sensitive detection for immunohistochemistry, immunocytochemistry, and in situ hybridization, enabling reproducible visualization of low-abundance targets. Its HRP-catalyzed tyramide chemistry delivers 100-fold signal amplification, streamlining workflows for high-resolution and cost-efficient cellular imaging.

• Dopaminergic Modulation of Bladder Function in PD Rat Models

  2026-05-24

  This study investigates the effects of the D1/D2-like agonist rotigotine on lower urinary tract function in a rat model of Parkinson’s disease (PD), revealing dose-dependent modulation of micturition reflexes. Findings highlight the significance of dopaminergic pathways in non-motor PD symptoms and offer translational insight for future research on receptor-targeted therapies.

• Dual Metabolic Nanoplatform Enhances Ferroptosis in TNBC The

  2026-05-23

  This study introduces a dual metabolic reprogramming strategy using a metal-polyphenol nanoplatform to overcome ferroptosis resistance in triple-negative breast cancer (TNBC). By co-targeting DHODH and DGAT1, the approach addresses compensatory survival mechanisms and demonstrates promising therapeutic efficacy in vitro and in vivo.

• Neticonazole Hydrochloride: Reliable Solutions in Oncology &

  2026-05-22

  This article provides scenario-driven, evidence-based guidance for laboratory teams evaluating Neticonazole Hydrochloride (SKU C8715) from APExBIO. We address real-world challenges in cell viability, cytotoxicity, and exosome inhibition workflows, offering practical protocol insights and comparing vendor options to support reproducible, high-impact research.

• Belinostat (PXD101): Empowering Precision in HDAC Inhibition

  2026-05-22

  Belinostat (PXD101) sets a benchmark for reproducible, sensitive histone deacetylase inhibition in cancer research. This article translates cutting-edge reference findings into actionable workflows, troubleshooting strategies, and protocol enhancements—enabling researchers to extract meaningful insights from complex tumor models.

• 10074-G5: Precision c-Myc Inhibition for Functional Cancer M

  2026-05-21

  Explore how 10074-G5, a potent c-Myc inhibitor, enables advanced cancer research through precise disruption of c-Myc/Max dimerization. This article delivers actionable protocol insights and unique analysis for translational oncology workflows.

• Nadolol (SQ-11725) Protocols for Hypertension Research Succe

  2026-05-21

  Nadolol (SQ-11725) from APExBIO stands out as a cornerstone for robust, reproducible hypertension and angina research thanks to its non-selective beta-adrenergic blockade and OATP1A2 substrate properties. This article distills advanced experimental workflows, pharmacokinetic insights, and hands-on troubleshooting guidance to empower cardiovascular investigators.

• Abiraterone Acetate: CYP17 Inhibitor Workflows in 3D Prostat

  2026-05-20

  Unlock reproducible androgen biosynthesis inhibition in advanced prostate cancer research with Abiraterone acetate. This guide outlines optimized workflows, 3D spheroid applications, and troubleshooting insights for maximizing data quality in translational models using APExBIO’s validated CYP17 inhibitor.

• Technical Guide: Hoechst 33342/PI Double Staining Kit (K2237

  2026-05-20

  The Hoechst 33342/PI Double Staining Kit enables rapid, fluorescence-based detection and differentiation of apoptosis and necrosis in cell cultures by targeting nuclear condensation and membrane integrity. This product is designed for basic research workflows and is not suitable for diagnostic or medical use.

• miR-196a Drives Esophageal Adenocarcinoma via MYC/TERT/NFκB

  2026-05-19

  This study identifies microRNA-196a as a key driver of esophageal adenocarcinoma aggressiveness through coordinated activation of the MYC/TERT/NFκB axis. The findings clarify a mechanistic link between miR-196a, epithelial-to-mesenchymal transition, and enhanced tumorigenic potential, opening the door for targeted interventions in cancer research.

• Moxidectin Potentiates Nystatin Against Candida albicans via

  2026-05-19

  A recent study reveals that moxidectin enhances ergosterol biosynthesis in Candida albicans, amplifying the antifungal action of polyenes like nystatin. This synergy significantly suppresses C. albicans growth and biofilm formation, offering a promising strategy against oral candidiasis and antifungal resistance.

• Testosterone Bounce as a Prognostic Biomarker in Degarelix T

  2026-05-18

  This study demonstrates that a 'testosterone bounce'—defined by specific serum testosterone fluctuations—predicts improved overall and cancer-specific survival in prostate cancer patients treated with the GnRH receptor antagonist Degarelix acetate. These findings advance biomarker-driven stratification in hormone therapy, supporting more nuanced prognostic assessment beyond PSA monitoring.

• Abiraterone Acetate: CYP17 Inhibitor Workflows in Prostate C

  2026-05-18

  Abiraterone acetate, a potent CYP17 inhibitor, enables advanced prostate cancer research by facilitating robust androgen biosynthesis suppression in both 2D and 3D spheroid models. This article provides practical, literature-backed workflows, troubleshooting guidance, and innovative use-cases to maximize translational impact in castration-resistant prostate cancer studies.

• Neticonazole Hydrochloride: Applied Protocols in Antifungal

  2026-05-17

  Neticonazole Hydrochloride, a dual-action imidazole antifungal, uniquely bridges antifungal workflows with cutting-edge colorectal cancer models through exosome pathway inhibition and apoptosis modulation. This article details protocol parameters, troubleshooting strategies, and recent nanomedicine advances to maximize experimental success.

16313 records 1/1088 page Next 12345 下5页 Last page